Janssen Follows AbbVie To Exit From Morphic Deal, But Lead Asset Still Has Chance

Morphic said that Janssen had chosen to exit the partnership formed in 2019, just a little more than half a year after AbbVie did the same.

Janssen exited its four-year-old deal with Morphic • Source: Shutterstock

In the space of just over half a year, Morphic Therapeutic, Inc. has lost two partnerships with major biopharma companies to develop its orally available integrin inhibitor drugs. However, the company still has growth prospects in the form of a Phase IIa asset in ulcerative colitis.

In a Securities and Exchange Commission filing on 20 January, Morphic said it had received notice from Johnson &...

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.